Biotech stocks have performed well this year. The SPDR S Biotech ETF -- an industry benchmark -- is up 21% this year. Two giants of the industry that have helped drive that performance are (NASDAQ: AMGN) and Gilead Sciences (NASDAQ: GILD). These well-known drugmakers have seen positive developments recently, leading to superior returns.

And the best news is that they still have plenty to offer investors, especially those looking for solid income stocks. Here is why Amgen and Gilead Sciences are great dividend stocks to buy.

Image source: Getty Images.

Continue reading

Source Fool.com